Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07

18 May 2012

Abstract excerpt

The O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive parameter for the response of malignant gliomas to alkylating agents such as temozolomide. First clinical trials with temozolomide plus bevacizumab therapy in metastatic melanoma patients are ongoing, although the predictive value of the MGMT promoter methylation status in this setting remains unclear. We assessed MGMT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Cancer Cells and Metastasis
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22614944
DOI: 10.3892/or.2012.1826

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07PMID 22614944Read ↗

Genomic and Molecular Profiling Predicts Response to Temozolomide in MelanomaSemantic proximity Read ↗

Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomasSemantic proximity Read ↗

Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: A Portuguese multicentre studySemantic proximity Read ↗

CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary GliomasSemantic proximity Read ↗

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary GlioblastomaSemantic proximity Read ↗

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcomeSemantic proximity Read ↗

O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanomaSemantic proximity Read ↗

Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter regionSemantic proximity Read ↗

Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastomaSemantic proximity Read ↗

Clinical Trial Substantiates the Predictive Value of <b> <i>O-6-Methylguanine-DNA Methyltransferase</i> </b> Promoter Methylation in Glioblastoma Patients Treated with TemozolomideSemantic proximity Read ↗

DNA methylation characteristics of primary melanomas with distinct biological behaviour.Semantic proximity Read ↗

Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.